Опубликована: Янв. 1, 2024
Язык: Английский
Biochemistry and Biophysics Reports, Год журнала: 2025, Номер 41, С. 101948 - 101948
Опубликована: Фев. 11, 2025
Язык: Английский
Процитировано
0
Biochemistry and Biophysics Reports, Год журнала: 2025, Номер 42, С. 101998 - 101998
Опубликована: Апрель 5, 2025
Язык: Английский
Процитировано
0
Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)
Опубликована: Апрель 18, 2025
Tumor-Associated Macrophages (TAMs) are the main immune component of tumor stroma with heterogeneous functional activities, predominantly suppressing response and promoting progression, also via secretion different factors. Among these, GPNMB (Glycoprotein non-metastatic B) is usually associated disease progression in several types. Malignant pleural mesothelioma (MPM) a severe neoplasia poor prognosis, characterized by an abundancy TAMs, testifying presence long-lasting inflammation which pathogenetic disease. However, role MPM unclear. Clinical samples from patients were used to measure RNA protein levels GPNMB. The vivo was studied orthotopic mouse model using murine cell lines AB1 AB22. Experiments included growth wild type GPNMB-deficient mice blocking GPNMB-induced signaling anti-CD44 antibodies. We show that human tissues mainly produced infiltrating TAMs. Gpnmb TCGA significantly lower survival. Using we observed GPNMB-defective (DBA2/J mice) unable produce protein, tumors formed AB22 cells grow less than GPNMB-proficient (DBA2/J-Gpnmb+ mice), indicating host involved progression. Likewise, ectopic expression causes acceleration vivo, compared mock-transduced cells. Treatment tumor-bearing (a major receptor for GPNMB) results significant reduction growth. Overall, these indicate GPNMB, product marker gene driver may constitute promising therapeutic target.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(17), С. 9190 - 9190
Опубликована: Авг. 24, 2024
CD44 regulates cell adhesion, proliferation, survival, and stemness has been considered a tumor therapy target. possesses the shortest standard (CD44s) variety of variant (CD44v) isoforms. Since expression CD44v is restricted in epithelial cells carcinomas compared to CD44s, promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C
Язык: Английский
Процитировано
3
Опубликована: Авг. 6, 2024
CD44 regulates cell adhesion, proliferation, survival, and stemness has been considered a tumor therapy target. possesses the shortest standard (CD44s) variety of variant (CD44v) isoforms. Since expression CD44v is restricted in epithelial cells carcinomas compared to CD44s, promising target for monoclonal antibody (mAb) therapy. We previously developed an anti‐CD44v10 mAb, C44Mab-18 (IgM, kappa) recognize exon 10-encoded region. In present study, mouse IgG2a version (C44Mab-18-mG2a) was generated evaluate antitumor activities against CD44-positive with established anti-pan C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity C44Mab-46-mG2a CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) oral squamous carcinoma lines (HSC-2 SAS) flow cytometry. exerted superior antibody‐dependent cellular cytotoxicity (ADCC) CD44v3–10. contrast, showed complement‐dependent (CDC) A similar tendency observed ADCC CDC HSC-2 SAS. Furthermore, administering or significantly suppressed CD44v3–10, HSC-2, SAS xenograft growth control IgG2a. These results indicate that could be therapeutic regimen CD44v10-positive tumors.
Язык: Английский
Процитировано
0
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0